# SynAct Pharma > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/synactpharma). ## Overview SynAct Pharma AB is a clinical stage biotechnology company based in Lund, Sweden, specializing in the resolution of inflammation through the selective activation of the melanocortin system. The company develops a portfolio of oral and injectable selective melanocortin agonists aimed at treating autoimmune and inflammatory diseases. SynAct Pharma's business model focuses on advancing projects to clinical proof-of-concept, specifically targeting Phase 2 studies, before entering commercial agreements with major pharmaceutical companies. The company is listed on Nasdaq Stockholm and operates through its subsidiaries in Denmark and Switzerland. ## Products & services • Oral selective melanocortin agonists • Injectable selective melanocortin agonists • Resomelagon (AP1189) for rheumatoid arthritis • Peptide-based melanocortin receptor agonists • Clinical development services - **Melanocortin Agonists** (50%) — Includes oral and injectable compounds for inflammation resolution. - **Clinical Development** (30%) — Services related to advancing clinical trials to Phase 2. - **Research Collaborations** (20%) — Collaborative projects with research institutions. - Oral selective melanocortin agonists - Injectable selective melanocortin agonists - Resomelagon (AP1189) for rheumatoid arthritis - Peptide-based melanocortin receptor agonists - Clinical development services ## Customers SynAct Pharma primarily targets pharmaceutical companies interested in innovative treatments for autoimmune and inflammatory diseases. Their customer base includes large pharmaceutical firms looking to license new therapies after proof-of-concept is established. Additionally, they collaborate with research institutions for the development of new drug candidates. The company's focus on non-suppressive therapies appeals to companies seeking alternatives to traditional immune-suppressive treatments. - **Pharmaceutical Companies** (primary) — They license therapies post proof-of-concept for autoimmune diseases. - **Research Institutions** (secondary) — Collaborate on developing new drug candidates. - **Biotech Firms** (emerging) — Interested in non-suppressive inflammation therapies. - Pharmaceutical companies seeking new therapies for autoimmune diseases - Research institutions collaborating on drug development - Companies interested in licensing innovative inflammation treatments - Partners looking for non-suppressive therapy options ## Geography SynAct Pharma is headquartered in Lund, Sweden, and operates through subsidiaries in Denmark and Switzerland. The company is listed on Nasdaq Stockholm, providing it with a strong presence in the European market. Its strategic location in Scandinavia allows for collaboration with leading research institutions across Europe. The company's geographic focus supports its business model by facilitating access to European regulatory bodies and potential partners. - Headquartered in Lund, Sweden - Subsidiaries in Denmark and Switzerland - Listed on Nasdaq Stockholm - Strong presence in the European market - Collaborations with European research institutions ## Strategy SynAct Pharma's strategic priorities include advancing its lead compound, resomelagon, through Phase 2 clinical trials and securing strategic partnerships with major pharmaceutical companies. The company aims to expand its therapeutic applications to include acute inflammation due to viral infections. By focusing on non-suppressive therapies, SynAct Pharma seeks to differentiate itself in the competitive biotech landscape. The company is also exploring opportunities for geographic expansion to enhance its market reach. - **Advance resomelagon in clinical trials** (medium-term) — To establish proof-of-concept and attract partners. - **Expand therapeutic applications** (long-term) — To address larger markets such as viral infections. - **Secure strategic partnerships** (short-term) — To facilitate commercialization and market entry. - Advance resomelagon through Phase 2 trials - Secure partnerships with major pharmaceutical companies - Expand therapeutic applications to viral infections - Focus on non-suppressive therapies for differentiation - Explore geographic expansion opportunities ## Risks Key risks for SynAct Pharma include the inherent uncertainties of drug development, such as clinical trial outcomes and regulatory approvals. The company also faces competition from other biotech firms developing similar therapies. Financial risks include the need for continuous funding to support R&D activities. Additionally, currency fluctuations and changes in regulatory requirements could impact operations. The company's reliance on partnerships for commercialization poses a strategic risk if suitable partners are not secured. - **Clinical trial outcomes** [critical] — Uncertainty in achieving desired results. - **Regulatory approval** [high] — Complex and evolving requirements. - **Competition** [high] — Other firms developing similar therapies. - **Funding requirements** [high] — Need for continuous investment in R&D. - Uncertainties in clinical trial outcomes - Regulatory approval challenges - Competition from other biotech firms - Need for continuous R&D funding - Currency fluctuations affecting operations - Dependence on strategic partnerships ## Accounting SynAct Pharma's financial reporting is subject to IFRS standards, with critical accounting matters including the recognition of R&D expenses and the valuation of intangible assets. The timing of revenue recognition from potential partnerships is crucial, as it impacts financial projections. The company's financial statements may also be affected by currency fluctuations due to its international operations. Provisions for clinical trial costs and potential liabilities are significant judgment areas that impact reported numbers. - **R&D expense recognition** - **Intangible asset valuation** - **Revenue recognition timing** - Recognition of R&D expenses impacts financial results - Valuation of intangible assets affects balance sheet - Revenue recognition timing from partnerships is crucial - Currency fluctuations impact financial statements - Provisions for clinical trial costs require judgment --- *Last updated: 2026-08-11T04:04:56.497722+00:00*